Pharma Leaders Rate Diagnostic Action at 5.2 of 10

A Diaceutics survey of 125 US pharma leaders finds gaps in turning diagnostic insights into treatment for eligible patients.

Updated on Nov. 19, 2026 in Healthcare

Pharma Leaders Rate Diagnostic Action at 5.2 of 10

Diaceutics published a survey of 125 US pharma leaders rating their organizations' ability to act on diagnostic insights at 5.2 out of 10. The findings informed the launch of its Precision for All Strategic Collaboration initiative.

Why it matters

Respondents rated diagnosis-to-treatment conversion at 7.5 out of 10 for its importance to future commercial success, suggesting that identifying patients is only part of the challenge. Access and reimbursement barriers, along with late testing, were cited as the most common reasons eligible patients fail to receive appropriate therapy.

The survey of 125 respondents, 85% of whom hold Director-level positions or above, rated confidence in identifying eligible patients at 6.6 out of 10 and visibility across the patient journey at 5.4 out of 10. Self-reported ratings are not independently verified, and the survey does not measure actual patient outcomes.

The players

Diaceutics

Diaceutics is a healthcare analytics company that works with pharmaceutical organizations on diagnostic data and patient identification strategies.

The details

The survey was conducted with 125 US pharma leaders and asked them to rate their organizations' diagnostic conversion capabilities. Diaceutics then launched its Precision for All Strategic Collaboration, which brings together senior leaders from across the pharmaceutical industry, with an initial discussion involving representatives from several top 20 pharma organizations.

Timeline

  1. November 18, 2026: Diaceutics published the survey findings.

Health Landscape

The survey findings feed directly into the Precision for All Strategic Collaboration, which aims to address the gap between diagnosis and treatment that respondents identified as a commercial priority. The initiative positions diagnostic conversion as a shared industry problem rather than an individual company concern.

For patients, the survey points to access and reimbursement barriers and late testing as reasons eligible individuals may not start appropriate therapy. Patients whose diagnosis is delayed or whose coverage is uncertain may benefit if industry collaborations succeed in closing these gaps.

The takeaway

Closing the gap between identifying patients and treating them depends on access, reimbursement, and timely testing, not diagnosis alone. Readers following drug access issues can watch whether the Precision for All initiative produces concrete, shared solutions.

Further reading

Explore more coverage of the Healthcare sector for context on how drug access and diagnostics shape pharmaceutical commercial strategy.

Source note: This article includes information reported by News-Medical.